Clinical Trial Update: Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy [Phase 2]

View source ↗

Summary

Novartis' Phase 2 trial evaluating four doses of QGE031 in adults with peanut allergy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• QGE031

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Peanut Allergy | Phase 2 | Status: WITHDRAWN